Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Done! Now, if mods would just delete dozens of useless, repetitive posts every day, I would read this board more often. TIA.
New Images Show Virus Dismantled by Broad-Spectrum NanoViricides Electron Micrographs Confirm Virus Destruction
Hartford - June 28, 2007
Hartford -- In startling new imagery, a drug developed by NanoViricides, Inc. (Pink Sheets: NNVC) dismantles a virus particle in a visual demonstration of the novel mechanism of action of nanoviricides in vitro.
NanoViricides’ President Dr. Anil Diwan unveiled the electron micrographs at the Nano Science and Technology Institute’s (NSTI) Nanotech2007 Conference in Santa Clara, CA, May 24. An abstract of the presentation can be viewed at BioNano: NanoMedicine, Diagnostics, Imaging & Therapies (http://www.nsti.org/Nanotech2007/showabstract.html?absno=281).
The electron micrograph can be seen on the company’s website at NanoViricides Dismantling MCMV as seen in TEM (http://www.nanoviricides.com/nnvc-tem.pdf).
Different broad-spectrum nanoviricides were shown to dismantle the envelope coat of the murine cytomegalovirus, (mCMV) releasing the virus capsids it contains. The released capsids, which contain the genome of the virus particle, are no longer infectious. “This is the first visual demonstration that nanoviricides attack viruses in vitro just the way we’ve designed them to do so,” said Dr. Diwan.
The murine CMV is closely related to the human CMV, which causes various diseases, including ocular diseases such as retinopathy and blindness, especially in immunocompromised patients such as HIV/AIDS cases. CMV has become a major management problem in persons living with AIDS and represents a therapeutic challenge to physicians caring for this population.
Dr. Diwan also presented survival data in mice infected with an otherwise lethal dose of rabies. “That the nanoviricides treatments enabled the animals to survive at all is a major breakthrough in rabies,” he noted.
“We now know that our broad spectrum drug candidates are capable of attacking H5N1 bird flu viruses of both Clade 1 and Clade 2 varieties, common influenzas, rabies, and also cytomegalovirus,” said NanoViricides’ CEO Eugene Seymour, MD, MPH.
“Just as ampicillin works against a wide range of bacteria, we believe broad-spectrum nanoviricides can be designed to work against a wide range of viruses,” he added further.
There can be no assurance that this demonstration or the results of our animal studies may ever lead to the development of a nanopharmaceutical product approved for commercial resale or that, if approved, a commercial market will develop for our products.
About NanoViricides: http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
Changing your tune again blackjack? Or should I say "rearranging your tune again" to fit your last story,lol.
Did you buy at .08? By the way, what nationality are you (Russian)? I am guessing you are new to English as evidenced by 8-10 grammar errors in your post.
UGNE up .15 on news:
http://www.investorshub.com/boards/read_msg.asp?message_id=20802210
UGNE up .15 on news:
http://www.investorshub.com/boards/read_msg.asp?message_id=20802210
Unigene and Yale Present Novel Site-Directed Bone Growth Technology for Strengthening Bones
8:00a ET June 27, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) and Yale University presented animal data this week demonstrating the ability to strengthen bone by a minimally-invasive surgical procedure followed by the administration of parathyroid hormone (PTH).
A poster entitled "Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation and Anabolic Therapy" was presented at the 17th Scientific Meeting of the International Bone and Mineral Society in Montreal, Canada. The presentation will be posted this week on Unigene's website, www.unigene.com.
"Although still in the early stages of development, we believe that this technology may represent an important breakthrough in the prevention and treatment of certain commonplace but serious medical conditions," commented Dr. Warren Levy, President and CEO of Unigene. "There is an important unmet need for a rapid, minimally-invasive procedure to strengthen specific bones that are at risk of fracture, or to accelerate fracture repair. If future animal and human studies confirm the utility of this technology, it could represent a much more attractive alternative for patients considering hip replacement, spinal fusion, vertebroplasty or other common bone-related surgeries."
About Site-Directed Bone Growth (SDBG)
The patent-pending SDBG technology involves the synergistic combination of a proprietary device to irrigate the marrow of a targeted bone and the systemic administration of a biological compound, such as PTH, that promotes bone growth. The appearance of new bone after only three weeks of PTH therapy was documented in study animals by various techniques and caused improvement in the strength and biomechanical properties of the targeted bone. The study results also demonstrated that the use of calcitonin following PTH treatment protected the new bone that was created. The amount of new bone observed following the combined use of PTH and calcitonin far exceeded that achieved by treatment with PTH or calcitonin alone.
In clinical practice, the technology may find application in skeletal sites such as the spine, hip or wrist for preventing fractures of bones weakened by osteoporosis, to accelerate fracture repair and bone healing, or to reinforce the implantation of prosthetic devices. The potential markets for these technologies include the prevention and/or treatment of vertebral compression fractures, hip fractures and long bone fractures. The market for products and procedures for each of these indications currently exceeds $1 billion annually. This technology may also be useful in treating chronic back pain, an indication involving expenditures of more than $5 billion in 2006.
Unigene has established an active collaboration with leading clinicians in interventional radiology, neurobiology and orthopedic surgery at Johns Hopkins Medical School to explore the various potential clinical applications of this technology.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.
SOURCE: Unigene Laboratories, Inc.
Unigene Investor: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Lynn Granito, 212-825-3210
Hey blackjack-it hit your .08 mark. Have you bought yet? Have you turned this around as you guaranteed????
They always do. Do you suppose he has been reported to SEC?
*** SUPER SHORT SQUEEZE REPORT ***
Paivis Corp (OTCBB: PAVC) IS SHORT APPOX 10,500,000 SHARES.
This is our first report to publish in 18 months; it took us almost
1 and a half years to find another HUGE opportunity for our
investment community.
Paivis Corp (OTCBB: PAVC) has a short position of approximately 10
million shares. The shorter sellers are expected to begin covering
during the next 5 trading sessions very heavily. We expect this one
to hit as high as 6.25 a share in the next 5 trading sessions, as
these short positions are being covered. We saw Paivis trading as
low as .18 last week as short sellers pounded the stock yet again.
Now we are seeing it climb up to the .39 per share mark.
Our first SQUEEZE trigger price of 1.05 is expected to be reached
as soon as Thursday, and then Friday we should pull through the
next two squeeze trigger prices of 1.41 and 1.63. When this happens
it will cause the massive volume spike and price increases as short
sellers must cover their positions.
PAVIS IS TRADING AT A HUGE DISCOUNT â" GET IN NOW!
DO NOT LET THIS ONCE IN A LIFETIME OPPORTUNITY PASS YOU BY - GET IN
BEFORE THE SQUEEZE TRIGGER PRICE IS HIT AND SENDS THIS ONE THROUGH
THE ROOF!!!
DOS-please keep deleting the dozens of useless posts on this board from people who have nothing better to do. Many of us miss the IMPORTANT AURC posts because we have no time to sift through all of the garbage. TIA
Industry news in brief
News Archives
All news for June 2007
All news for May 2007
26/06/2007 - LabTechnologist.com brings you its periodic round up of industry news with developments at Applied Biosystems, MFIC, Oxford Gene Technology, PerkinElmer and Syagen.
Applied Biosystems has opened a new application support centre at its R&D headquarters in foster City, California, US. The 10,000 sq.ft. facility will house a wide selection of the company's instrumentation and software offerings to allow customers to identify workflow improvements and develop new applications with the help of Applied Biosystems staff.
IntegraGen has become the first certified service provider for Illumina's GoldenGate and Infinium genotyping technologies in France.
"IntegraGen is a company dedicated to offering high-quality services to other research institutes, either private or academic, and is the first laboratory in France to achieve CSPro certification for GoldenGate and Infinium Genotyping," said Karen Possemato, director of corporate marketing at Illumina.
MFIC Corporation has opened a new R&D facility, dubbed the Microfluidics Technology Center, designed to assist in the company's quest to develop microfluidic technology for use in pharmaceutical formulation processes.
I would suggest you buy up to .01 :)
You could at least wait until I get more funds into my TDA account :)!
June 25, 2007 1:05 PM ETGAO: We're not ready for bird fluRelated information E-mail this article Print-friendly version Discuss this article
All bizjournals.com NewsA federal report says neither the U.S. government nor the states are ready for bird flu, though it has spread to 60 countries and will likely arrive here sooner or later.
"My home state is particularly vulnerable," said Sen. Daniel Akaka, D-Hawaii, "because of the number of visitors we receive from Asia, where many of the incidences of this disease have been identified. This virus could create a health as well as an economic crisis in our tourism-dependent state."
Recent investing newsHome System Group Announces Acquisition Agreement With Zhongshan City Weihe Appliances Co., LTDAsia Properties Moves Closer to Philippine Island AcquisitionProvidential Holdings Announces Completion of Oceanblue Investment's ReorganizationCruisestock, Inc. Shareholders Approve 7 for 1 Forward Stock Split Among Other Items At Special Shareholders MeetingInsmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
The Government Accountability Office report, issued Monday, says the U.S. Department of Agriculture has taken "important steps" to prepare for an outbreak of H5N1 avian influenza but said "better planning could improve response."
One potential obstacle to responding to a bird flu outbreak could be a squabble over jurisdiction, not between federal and state officials but between officials of different federal agencies. USDA takes the view that involvement by the Department of Homeland Security is not necessary unless there were multiple outbreaks, an agroterrorism event or a human pandemic. But GAO points out that this is not USDA's decision to make.
"After H5N1 enters the U.S. and makes people or animals sick is not the time to negotiate over who's in charge," Akaka said, adding that he was disappointed with the USDA for not coordinating with DHS over something that puts lives at risk.
GAO pointed out that terrorist involvement would likely be suspected regardless of circumstances because of the possibility that terrorists could introduce bird flu to disrupt the U.S. economy. The World Trade Center was targeted in 2001 precisely because it housed several large brokerage firms and the bombers thought its destruction would disrupt Wall Street.
GAO also reported that USDA has not estimated how much medicine is needed in the event of an outbreak. And it also said several states have no response plans or plans which are incomplete. The report was undertaken at the request of Akaka and several other senators, Republicans and Democrats alike.
Hawaii welcomes about 5 thousand visitors a day on flights from Asia. Most are from Japan, but there are also direct flights to Hawaii from Seoul, Taipei, Manila, Guam, Australia, New Zealand and several smaller Pacific Island nations.
ibreken-while I have had an issue with your constant bashing (without you owning shares) I completely agree with your post re "pump n dumpers". The SEC has those mentioned on their "list".
They were trying to drive the price up so they could sell to those without a clue (now most of those 'pumpers' are long gone btw). Who is worse?
June 26, 2007 06:00 AM Eastern Daylight Time
Health Canada Approves ADVR’s Application for Clinical IND
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today that a Clinical Trial Application for the use of AVR118 in cancer patients has been approved by the Therapeutic Products Division of Health Canada. This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.
“Our objective in seeking regulatory approval in Canada is to expand our clinical trial network in sites where we can accrue patients quickly and efficiently,” said Stephen M. Elliston, President and CEO of Advanced Viral Research Corp. “Large Canadian academic healthcare institutions typically enroll a higher proportion of patients into NCI-sponsored trials than their U.S. counterparts. Furthermore, the U.S. FDA recognizes Canadian centers as being fully compliant with U.S. clinical standards,” added Elliston.
Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials, including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.
Contacts
The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939
June 26, 2007 06:00 AM Eastern Daylight Time
Health Canada Approves ADVR’s Application for Clinical IND
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today that a Clinical Trial Application for the use of AVR118 in cancer patients has been approved by the Therapeutic Products Division of Health Canada. This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.
“Our objective in seeking regulatory approval in Canada is to expand our clinical trial network in sites where we can accrue patients quickly and efficiently,” said Stephen M. Elliston, President and CEO of Advanced Viral Research Corp. “Large Canadian academic healthcare institutions typically enroll a higher proportion of patients into NCI-sponsored trials than their U.S. counterparts. Furthermore, the U.S. FDA recognizes Canadian centers as being fully compliant with U.S. clinical standards,” added Elliston.
Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials, including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.
Contacts
The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939
NightKilla-we continue to wait on the PR your dependable source promised.
Speaking of sucker plays in ibox, here is a good board to check some out:
http://www.investorshub.com/boards/board.asp?board_id=7707
Feevro-have you contacted Interpol about your opinion of the possibility of a scam? I ASKED BLACKJACK THIS QUESTION THREE TIMES AND HE EVIDENTLY WAS TOO SCARED TO ANSWER.
http://www.interpol.int/Public/FinancialCrime/Default.asp
Penny newbies: check to see if scammers are after you before buying. It is not always the company scamming but a group of crooks who buy then email spam/scam the heck out of it. You buy while the crooks are dumping!
http://www.investorshub.com/boards/board.asp?board_id=7707
mthead-I had two deleted awhile back by a board censor.One was me posting that I was tired of hearing posters blaming naked shorters for pps and the other was deleted asking why 1st one was deleted,lol.
Foreign stock email spam/scammers trying to steal your money:
http://www.investorshub.com/boards/read_msg.asp?message_id=20698094
Foreign email spam/scammers:
Montag 25. Juni!
Firma: MOBILEMAIL US
Kurzel: MM1
Wertpapier-Kenn-Nummer: A0M LLZ
I-SIN : US 60742Q-1094
Letzter Preis: 0.26
4T Prog.: 0.90
FUGEN SIE MM1 IN IHRE LISTE MONTAG 25. JUNI!
Verzicht: Diese Anzeige wurde gesendet, um dich uber diese Firma zu
informieren. Deine eigene Forschung tun, bevor Sie kaufen. Der Absender
wurde $25.000 fur diese Sendung ausgeglichen.
SREA spam/scammers still pumping like crazy. Received 8-10 emails last two days all from different addresses.
Score One Inc.(SREA)
$0.30
News hit just after close. SREA has acquired the $75 Million peace of
land for the new "Recreation Town" in Dalian. This new project mimics a
Facility in "Shui On" that profited more than $100 Million USD. SREA is
going to go through the roof after this hits investors this weekend.
Get
on SREA at open on Monday
No guy-you are actually wearing the tinfoil hat. My comment was TIC to the ostriches who claim the OSC is "out to get Sulja".
You guys are right on the money. The OSC has a scheme going against Sulja!
NightKilla-have you had any contact with your "dependable source"?
Posted by: NightKilla
In reply to: None Date:6/20/2007 11:48:44 AM
Post #of 43125
I don't post much on these message boards, but thought this might help some in this terrible time. I'm a large pbls shareholder and according to my dependable source, there will be a pr before the opening bell tom. Do your own DD if looking to buy, please do not buy based on what I've said in this post. Good luck all
He (MAB) was one of the boards biggest pumpers-saying pps would go to $25!
From someone who says they attended annual meeting (and thanks):
By: andre726
21 Jun 2007, 03:40 PM EDT
Msg. 12381 of 12381
Jump to msg. #
Annual meeting
Real quick as I've got much to do during this return trip to the Boston area:
Started out with a recitation of the vote results. Interestingly, votes withheld ranged up to 800,000 for EACH of the directors. Never happened before in my experience. Still, all votes passed with 8 million or so FOR.
Official meeting adjourned. Chairman Little went through a presentation about MFIC. Not bad....perhaps even good....which included the company's alleged objective of being listed on AMEX within twelve months.
Then, questions. I was the only one who asked. There was apparently an investor or two there aside from me...but they remained silent.
First question: operating expenses far too high, sales expense in particular too high. I compared Q1 2006's $3,050,000 and Q1 2007's $2,800,000 revenues and pointed out that Q1 2007's selling expense was $200,000 plus thousand HIGHER despite its revenues being $350,000 LOWER.
Chairman Little pointed out that operating expenses were about the same as Q4 2006 (which, in my opinion, is nothing to brag about since revenues were a whopping $2,240,000 lower) and then asked Dennis Riordan to comment. He then went into his "we already answered that during the conference call and it has to do with adding new salespeople" response.
My response: "Yes. I know that's what you said during the conference call. And as I knew that the conference call was being recorded for prosperity, I didn't pursue the matter any further than I did...."
Suffice to say they had no answer to my question as to how Q1 2007's sales expense was $100,000 higher than Q3 2006 when Q3 2006 was a $3.553 million quarter (i.e., $750,000 higher than Q1 2007), especially since the new salespeople had been hired BEFORE Q3 2006. They had no answer to my question about "are they being paid $300,000 each in base annual salary in light of four new sales resources being paid $300,000 more during a single quarter as compared to Q1 2006 (the lesser Q1 2007 revenues resulting in $97,000 less in commissions being paid out such that the increase in sales expenses was actually closer to $300,000).
Dennis Riordan tried to say something about Q1 2007 actually being a $3.5 million quarter if those $800,000 worth of equipment had been shipped out by the end of Q1 2007. I asked him if any commissions were paid on those sales in that it was my understanding that commissions are paid upon shipment. He acknowledged, "No".
He then said it was something he would look into.
Second question: Japan sales. 2004 average: $625,000 per quarter. Q4 2006: $125,000. Q1 2007: $196,000. Suffice to say that, after hearing the same BS about constant pressure reducing the need for replacement parts (20 years of lab equipment sales involved NO constant pressure and only a handful of constant pressure production machines were sold to Japan since 2005), there was general recognition that there was a serious problem that needed to be looked into immediately as a top priority management exercise.
Third question related to the horrendous inconsistency in the messages delivered on March 29 and April 2.
Chairman Little said that was the last question (I actually had several more) and asked everyone to make their way to the new lab.
I figured that the lab would look very much like a lab....and left to proceed with my day.
So...the Board of Directors have been made aware of some things to be looked into. We'll see if any positive changes occur as a result.
IG was there sitting apart from other Directors. I was not made aware of any new hiring of a new IR person.
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
Will it ever, ever reach .01 again?
lol, I am only going to be patient with SLJB until Nov 2007!
MFIC Announces Opening of Microfluidics Technology Center
Innovation Hub Dedicated to Advancing the Micro- and Nano-Formulation Fields
Jun 21, 2007 7:00:00 AM
Copyright Business Wire 2007
NEWTON, Mass.--(BUSINESS WIRE)--
MFIC Corporation (MFIC or the Company)(OTCBB: MFIC) today announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility located at the MFIC company headquarters in Newton, MA. MFIC is an industry-leader in fluid formulation processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.
"The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics' technology and pursuing groundbreaking work in the field of nanotechnology," said Dr. Thomai Panagiotou, Vice President of Research and Development. "We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers--including potentially life-saving drugs--that to date could not be formulated."
The Microfluidics Technology Center will provide customers full access to the Company's R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving their existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer(R) materials processors.
"The opening of the Center demonstrates our ongoing commitment to advancing the industry and to providing the highest quality of service to our customers," said Bob Bruno, President and Chief Operating Officer. "While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to the best engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers' unique needs in mind."
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Please fill me in. Is there still a slight delay?
Please be advised that the financials which were promised on November 15 2006 will be
posted shortly. We have experience a slight unforeseeable delay. This delay will be
address by 4am EST and the financials will be posted at that time or shortly after.
A new CEO statement will be posted early on November 16 2006 explaining the delay
and matters concerning the financials. It is our intention to post this statement prior to
posting the financials.
We sincerely apologize if this has caused any problems to our shareholders; it is clearly
not our intention to do so.
Thank you all for your patience, understanding, and continued support.
Petar Vucicevich
I would bet the SEC could be interested in talking to your "dependable source".
Hey ed, I learn from my mistakes. How about you?
Yeah, better get some before Petards next PR or you will be an empty bagholder,lol.